

Phone: 404-585-7517 Fax: 404-900-9209 NPI: 1811550528 synergenrx.com

#### GI and HEPATOLOGY, ANCILLARY REFERRAL FORM (A-M)

PATIENT INFORMATION (please attach insurance card)											
Name:					М	□F	DoB:				
Street:	et:			ty:			State:	Zip:	Zip:		
Phone:		Phone:			Allergies	:		I			
CLINICAL INFORMATION (please attach clinical notes and labs)											
Diagnosis with ICD-10 code       □ A04.7 enterocolitis due to Clostridium difficile       □ B96.81 H. pylori infection         □ K50.90 Crohn's disease, unspecified       □ K51.91 ulcerative colitis, unspecified       □ K52.2 chronic diarrhea, noninfection         □ K52.832 lymphocytic colitis       □ K52.839 microscopic colitis       □ K74.3 primary biliary cholangitis         □ K76.82 hepatic encephalopathy       □ K92.2 gastrointestinal hemorrhage, unspecified       □ Other:											
□ CMP □ <i>C diff</i> tox		PCR antimito	chondrial	antibody	□ colon	oscopy wit	h tissue biopsy,	date:			
Treatment History  Current medication(s) with date(s) started:  Prior medication(s) with dates of use:											
PRESCRIPTION	N .								□ DAW		
Medication	Do	se/Strength			Direc	Quantity	Refills				
balsalazide	7	50mg capsule									
□ budesonide	☐ 4mg DR ☐ 6mg ER	capsule (Entocort capsule (Tarpeyo) capsule (Ortikos) tablet (Uceris)	EC)								
☐ cholestyramine		4g packet									
colestipol	□ 5g packe	et 🗆 1g tablet									
☐ Dificid		200mg tablet		take 1 ta	blet by mo	uth twice d	aily for 10 days	for 10 days			
□ mesalamine	☐ 4g recta ☐ 4g/60ml ☐ 250mg E ☐ 400mg [ ☐ 500mg E ☐ 800mg [ ☐ 1000mg	ER capsule (Apriso) kit (Rowasa) Lenema (Rowasa) ER capsule (Pentasa) ER capsule (Delzico ER capsule (Pentasa) ER tablet (Asacol H suppository (Cana tablet (Lialda)	a) il) a) D)								
PRESCRIBER I	NFORM <i>A</i>	TION									
Prescriber:						g Physician					
Contact Name:				Method:		□Fax □	]Email:				
Phone:			Ext:	···	Fax:		Chal	<del></del>			
Street:				City:	<b>.</b>		State:	Zip:			
Signature:				Da	te:		NPI:				



Phone: 404-585-7517 Fax: 404-900-9209 NPI: 1811550528 synergenrx.com

### **GI and HEPATOLOGY, ANCILLARY REFERRAL FORM (M-Z)**

PATIENT INFORMATION (please attach insurance card)										
Name:			М [	□ F	DoB:					
Street:			City:			St	ate:	Zi	p:	
Phone:	Phone:			Allergies:		<u> </u>				
CLINICAL INFORMATION (please attach clinical notes and labs)										
Diagnosis with ICD-10 code       □ A04.7 enterocolitis due to Clostridium difficile       □ B96.81 H. pylori infection         □ K50.90 Crohn's disease, unspecified       □ K51.91 ulcerative colitis, unspecified       □ K52.2 chronic diarrhea, noninfection         □ K52.832 lymphocytic colitis       □ K52.839 microscopic colitis       □ K74.3 primary biliary cholangitis         □ K76.82 hepatic encephalopathy       □ K92.2 gastrointestinal hemorrhage, unspecified       □ Other:         Labs & Procedures       (please send copies of the most recent applicable results)								oninfectious		
□ CMP □ C diff to:	kin □ <i>C diff</i> PCR □ antimito	chondrial	l antibody	□ colono	scopy with	n tissue	biopsy, da	te:		
Treatment History  Current medication(s) with date(s) started:  Prior medication(s) with dates of use:										
PRESCRIPTION	N .								□ DAW	
Medication	Dose/Strength			Direct	tions/S	ig		Quantity	Refills	
☐ megestrol	Susp: ☐ 40mg/mL ☐ 400mg/10mL ☐ 625mg/5mL ☐ 800mg/20mL Tabs: ☐ 20mg ☐ 40mg									
□ octreotide	IM kit: □ 20mg □ 30mg PFS: □ 50µg/mL □ 100µg Vial: □ 50µg/mL □ 100µg □ 200µg/mL									
sulfasalazine	□ 500mg tab □ 500mg DF	R tab								
☐ Talicia	10mg-250mg-12.5mg cap	os	4 caps PO	3 times da	14 days					
☐ ursodiol	Caps: □ 200mg □ 300m □ 400mg Tabs: □ 250mg □ 500m									
□ vancomycin	Caps: □ 125mg □ 250m Soln: □ 250mg/5mL	ıg	mg PO 4 times daily fordays							
☐ Xifaxan	550mg tablet		take 1 tablet by mouth twice daily							
Other:										
PRESCRIBER INFORMATION  Prescriber: Supervising Physician:										
Prescriber:  Contact Name:		Contact								
Phone:		Ext:	t Method: [	Phone	⊔rax ⊔	ı⊏maıl	:			
Street:			City:			State:		Zip:		
Signature:			Da	te:			NPI:			



#### GI BIOLOGICS REFERRAL FORM (A - D)

Phone: 404-585-7517 Fax: 404-900-9209 NPI: 1811550528 synergenrx.com

PATIENT INFORMATION (please attach insurance card) □ M  $\sqcap$  F City: Street: State: Zip: Phone: Phone: Allergies: CLINICAL INFORMATION (please attach clinical notes and labs) **Diagnosis with ICD-10 code** Clinical History ☐ K20.0 Eosinophilic Esophagitis Labs & Procedures (send copies of the most recent results) ☐ K50.90 Crohn's Disease, unspecified colonoscopy with tissue biopsy, date: \_ ☐ HBsAg ☐ EGD with tissue biopsy, date: ☐ K51.90 Ulcerative Colitis, unspecified --- intraepithelial eosinophil count  $\square \ge 15$  eosinophils per HPF ☐ < 15 eosinophils per HPF</p> Disease Staging □ mild Severity: height: \_\_\_\_\_ in/cm ☐ MAYO score: \_\_ ☐ moderate ☐ CDAI score: \_ ☐ severe **Treatment History** Current medication(s) with date(s) started: Prior medication(s) with dates of use: \_ PRESCRIPTION □ DAW (deliver to □ patient □ office) Medication Route Dose/Strength Directions/Sig Quantity Refills П Check this box to authorize the pharmacy to interchange to the plan's preferred biosimilar if needed Starter Kit (PF) ☐ Induction: inject 160mg (two adalimumab 80mg/0.8mL) sub-Q over 1-2 days then 0 ■ Pen: 80mg/0.8mL □ Abrilada □ Amjevita inject 80mg sub-Q on day 15 ■ PFS: 80mg/0.8mL ☐ Cyltezo □ Hadlima sub-0 **Pen (PF):** □ 40mg/0.4mL ☐ Hulio ☐ Humira Maintenance □ 40mg/0.8mL ☐ inject 40mg sub-Q every 2 weeks ☐ Hyrimoz ☐ Idacio **PFS (PF):** □ 40mg/0.4mL \_\_\_\_mg sub-Q every ☐ Simlandi ☐ Yuflyma ☐ 40mg/0.8mL weeks ☐ Yusimry ■ Vial: 200mg ☐ Induction: 400mg sub-Q weeks 0, 2, & 4 ☐ **PFS**: 6 x 200mg/mL Cimzia sub-Q Maintenance ■ Vial: 200mg ☐ inject 400mg sub-Q every 4 weeks **PFS**: □ 6 x 200mg/mL ☐ other: \_\_\_\_\_mg sub-Q every □ 2 x 200mg/mL weeks ☐ Adult: 300mg sub-Q once weekly **pen**: □ 200mg/1.14mL Pediatric: ☐ 300mg/2mL П Dupixent sub-0  $\square$  15 to < 30kg: 200mg every other week **PFS**: □ 200mg/1.14mL ☐ 30 to < 40kg: 300mg every other week ☐ 300mg/2mL  $\square \ge 40$ kg: 300mg once weekly PRESCRIBER INFORMATION Supervising Physician: Prescriber: Contact Name: Contact Method: ☐ Phone ☐ Fax ☐ Email: Phone: Fxt: Fax: State: Street: City: Zip: Signature: Date: NPI:



# GI BIOLOGICS REFERRAL FORM (E - R)

Phone: 404-585-7517 Fax: 404-900-9209 NPI: 1811550528 synergenrx.com

PATIENT INFORMATION (please attach insurance card) DoB:  $\sqcap$  F City: Street: State: Zip: Phone: Phone: Allergies: CLINICAL INFORMATION (please attach clinical notes and labs) **Diagnosis with ICD-10 code** Clinical History ☐ **K50.90** Crohn's Disease, unspecified Labs & Procedures (send copies of the most recent results) ☐ K51.90 ulcerative colitis, unspecified ☐ TB ☐ HBsAg Other: \_ colonoscopy with tissue biopsy, date: \_ ☐ mild Disease Staging Severity: height: \_\_ in/cm ☐ MAYO score: \_\_ ☐ moderate weight: lb/kg ☐ CDAI score: severe **Treatment History** Current medication(s) with date(s) started: \_ Prior medication(s) with dates of use: **PRESCRIPTION** □ DAW (deliver to □ patient □ office) Medication Route Dose/Strength Directions/Sig Quantity Refills П Check this box to authorize the pharmacy to interchange to the plan's preferred biosimilar if needed Intravenous ☐ Induction: 300mg IV at weeks 0, 2, & 6 □ vial: 300mg ☐ Maintenance: 300mg IV every 8 weeks □ IV Entyvio ☐ **pen**: 108mg/0.68mL □ sub-Q **Subcutaneous** ☐ **Induction**: 300mg IV at weeks 0 and 2 ☐ Maintenance: 108mg sub-Q every 2 wks ■ Induction: infuse ma (5ma/ka) □ vial: 100mg 0 infliximab IV at weeks 0, 2, & 6 □ IV <u>Maintenance</u> □ Avsola ■ Inflectra □ vial: 100mg □ IV: \_ □ sub-Q \_mg (5 or 10 mg/kg) every  $\_$ ☐ Remicade ☐ Renflexis ■ pen: 120mg/mL weeks beginning week 14 ☐ inj: 120mg mg sub-Q every 2 weeks ☐ Zymfentra □ **PFS**: 120mg/mL beginning week 10 Tabs: ☐ 45mg ☐ Crohn's: 45mg once daily x 12 weeks 28 0 ☐ **UC:** 45mg once daily x 8 weeks PO Rinvoq <u>Maintenance</u> Tabs: □ 15mg ☐ Crohn's: \_ mg PO once daily □ 30mg UC: \_\_ \_ mg PO once daily PRESCRIBER INFORMATION Prescriber: Supervising Physician: Contact Name: Contact Method: □Phone □Fax □Email: Phone: Ext: Street: City: State: Zip: Signature: NPI:



Signature:

## **GI BIOLOGICS**

Phone: 404-585-7517 Fax: 404-900-9209 **NPI**: 1811550528 synergenrx.com

**REFERRAL FORM (S - T)** PATIENT INFORMATION (please attach insurance card) DoB: □ F City: Street: State: Zip: Phone: Phone: Allergies: CLINICAL INFORMATION (please attach clinical notes and labs) **Diagnosis with ICD-10 code** Clinical History ☐ **K50.90** Crohn's Disease, unspecified Labs & Procedures (send copies of the most recent results) ☐ K51.90 ulcerative colitis, unspecified ☐ HBsAg Other: \_ colonoscopy with tissue biopsy, date: ☐ mild Disease Staging Severity: height: \_ ☐ MAYO score: \_ ☐ moderate weight: lb/kg ☐ CDAI score: severe **Treatment History** Current medication(s) with date(s) started: \_ Prior medication(s) with dates of use: **PRESCRIPTION** □ DAW (deliver to □ patient □ office) Medication Route Dose/Strength Directions/Sig Quantity Refills Check this box to authorize the pharmacy to interchange to the plan's preferred biosimilar if needed ☐ **Induction**: inject 200mg at week 0 then 0 inject 100mg at week 2 pen: 100mg/mL Simponi sub-Q □ PFS: 100mg/mL **Maintenance** ☐ inject 100mg sub-Q every 4 weeks other: \_ \_mg every \_ IV □ vial: 600mg/10mL ☐ Induction: 600mg IV at weeks 0, 4, & 8 30 0 Skyrizi П Crohn's **OBJ**: □ 180mg/1.2mL sub-Q ☐ Maintenance: \_\_\_\_ mg sub-Q every 8 weeks □ 360mg/2.4mL vial: 600mg/10mL ΙV ☐ **Induction**: 1,200mg IV at weeks 0, 4, & 8 60 0 Skyrizi **OBJ**: ☐ 180mg/1.2mL UC sub-Q ■ Maintenance: mg sub-Q every 8 weeks □ 360mg/2.4mL ΙV □ **vial**: 200mg/20mL ☐ **Induction**: 200mg IV at weeks 0, 4, and 8 60 Λ pen: ☐ 100mg/mL Tremfya ■ 200mg/2mL ■ Maintenance: ■ 100mg sub-Q every 8 weeks sub-Q PFS:□ 100mg/mL ■ 200mg sub-Q every 4 weeks ■ 200mg/2mL PRESCRIBER INFORMATION Supervising Physician: Prescriber: Contact Name: Contact Method: ☐ Phone ☐ Fax ☐ Email: Phone: Fxt: Fax: Street: City: State: Zip:

Date:

NPI:



## GI BIOLOGICS REFERRAL FORM (U - Z)

Phone: 404-585-7517 Fax: 404-900-9209 NPI: 1811550528 synergenrx.com

PATIENT INFO	RMATI	<b>ON</b> (plea	se attach insu	rance card	)							
Name:					М	□F	DoB:					
Street:				City:		'	State:		Zip:			
Phone:		Phone:			Allergies	5:		1				
CLINICAL INFORMATION (please attach clinical notes and labs)												
Diagnosis with IC	D-10 cod	<u>e</u>				<u>Clinical</u> H						
☐ <b>K50.90</b> Crohn's		·	Labs & Pro									
K51.90 ulcerative colitis, unspecified				☐ TB ☐ HBsAg ☐ CMP ☐ CBC								
			☐ colono	Colonoscopy with tissue biopsy, date:								
height:		in/cm	Disease Staging Severity: ☐ mild					_				
weight:		lb/kg	☐ MAYO sco☐ CDAI scor					<ul><li>☐ moderate</li><li>☐ severe</li></ul>				
<u>Treatment Histor</u>	v		L CDAI 3001	<u> </u>								
Current medication(s)	=	) started:										
Prior medication(s) wit	th dates of ı	use:										
PRESCRIPTIO	N					□ <b>D</b> .	<b>AW (</b> deliv	er to □patio	ent □office)			
Medication	Route	Dose/	Strength		Direc	tions/Sig	Quantity	Refills				
	Check this	box to auti	horize the pharr	nacy to inter	change to	the plan's	preferred biosi	milar if neede	d 			
ustekinumab Imuldosa Stelara Otulfi Stegeyma	IV	□ <b>vial:</b> 13	30mg/26mL	☐ <b>Induction</b> : infuse IV as a single dose ☐ 260mg (≤55kg) ☐ 390mg (55-858kg) ☐ 520mg (> 85kg)				60	0			
□ Pyzchiva □ Wezlana □ Selarsdi □ Yesintek □ Starjemza	sub-Q	□ <b>PFS</b> : 90	mg/mL	☐ Mainter	<b>nance</b> : 90n	ng sub-Q ever	ry 8 weeks					
		IR Tabs: ☐ 5mg ☐ 10mg XR Tabs: ☐ 11mg ☐ 22mg		☐ <b>ER</b> : 22r	ng PO once	or we						
☐ Xeljanz	PO	IR Tabs:	]5mg □10mg ]11mg □22mg	Maintenan ☐ IR: 5mg ☐ ER: 11r ☐ other: _	<b>ce</b> PO BID							
☐ Other:												
PRESCRIBER 1	INFORM	ATION						•				
Prescriber:					Supervisin	g Physician:						
Contact Name:			Cont	act Method:	 □ Phone	□Fax□	Email:					
Phone:			Ext:		Fax:							
Street:				City:			State:	Zip:				
Signature:				Da	ite:		NPI:					



Phone: 404-585-7517 Fax: 404-900-9209 NPI: 1811550528 synergenrx.com

**IRRITABLE BOWEL SYNDROME REFERRAL FORM** 

PATIENT INFOR	MATION (please attach i	insuranc	e card)								
Name:			_ N	4 □ F	DoB:						
Street:	et:			City: State:				ip:			
Phone:	Phone:	<u> </u>		Allergies:			ı				
CLINICAL INFO	RMATION (please attach	clinical	notes ar	nd labs)							
Diagnosis with ICD-10 code			If the diagnosis is <u>SIBO</u> , has the patient completed a diagnostic    yes    no breath test? If yes, please include results.								
□ A04.9 small intestine bacterial overgrowth (SIBO)			If the diagnosis is <u>IBS-D</u> , has the patient failed a ≥ 3 month								
☐ <b>K58</b> irritable bowel syndrome (IBS), unspecified ☐ <b>K58.0</b> irritable bowel syndrome with diarrhea (IBS-D)			If the diagnosis is <u>IBS-C</u> , <u>OIC</u> , or <u>CIC</u> , has the patient failed a   ≥ 3 month trial of dietary (increased water, fiber) and lifestyle								
□ <b>K58.1</b> irritable bowel syndrome with constipation (IBS-C) □ <b>K59.03</b> opioid-induced constipation (OIC)			(increased exercise) modifications?  • If the diagnosis is <u>OIC</u> , is the patient using the opioid(s) for □ yes □ r chronic, non-cancer pain?								
□ <b>K59.04</b> chronic idiopath □ Other:	ic constipation (CIC)	• If t	the diagnos	is is <u>OIC</u> , is the patie frequent titrations?	ent on a s	table opioid d	ose 🗆	yes	□ no		
PRESCRIPTION									DAW		
Medication	Product			Directions/	Sig		Quantity	,	Refills		
Constipation											
☐ Ibsrela	50mg tab		1 t	ablet PO twice daily	before me	eals					
Linzess	<b>Caps:</b> □ 72mcg □ 145mcg □ 2	90mcg	1 capsul								
lubiprostone (Amitiza)	Caps: ☐ 8mcg ☐ 24mcg		1								
☐ Motegrity	Tabs: □1mg □ 2mg										
Movantik	<b>Tabs:</b> □ 12.5mg □ 25mg		1 tablet F	O once daily 1-2 hou							
Relistor	Vial: □ 8mg/0.4mL □ 12mg/ Tabs: □ 150mg tab	/0.6mL		day(s) daily							
☐ Symproic	0.2mg tab			1 tablet PO once	daily						
☐ Trulance	3mg tab										
<u>Diarrhea</u>											
alosetron	Tabs: □ 0.5mg □ 1mg										
☐ Xifaxan	550mg tab		1 tab								
Other:											
PRESCRIBER IN	FORMATION										
Prescriber:		Su	pervising	Physician:							
Contact Name:	(	Contact M	ethod:	Phone  Fax	]Email:						
Phone:	E	Ext:		Fax:							
Street:		Ci	ty:	Stat	e:	Zip:					
Signature:			Date	2:		NPI:					

<sup>\*</sup>By signing this form, I authorize Synergen Rx LLC and its employees to act as authorized agents on behalf of my office to obtain prior authorization through my patient's insurance plan and to facilitate the enrollment of the patient into patient assistance programs with manufacturers and other foundations.